■念珠菌(C.auris),一种最近发展起来的高毒力真菌病,易于传输,以及医院的大量药物耐药性,对人类健康构成越来越大的威胁。2009年,在一位日本老年患者的耳道中发现了这种疾病的初步文献。自从最初的隔离以来,C.auris在六大洲的存在一直引起医学专家和科学家的严重关注。根据最近的调查结果,C.auris与五个地理上不同的谱系和显着的抗真菌耐药性相关。此外,在医疗保健环境中,弧菌感染缺乏适当的治疗选择和预防和控制的标准化策略。这会导致许多治疗失败,并阻碍医疗机构中C.auris的消除。目的:探讨金黄色葡萄球菌的耐药机制,为临床治疗提供帮助。我们提供一例金黄色葡萄球菌感染病例以及相关文献的简短回顾。
■一名患有脑出血的81岁女性入院,并被诊断为与导尿管相关的C.auris。对样本进行了评估,并在培养方面进行了报告,identification,药物敏感性,和基因测序。我们还评估了分离菌株的形态与其耐药性之间的关系。全基因组测序产生了基因ERG11-Y132F,CDR1-E709D,TAC1B-Q503E,和TAC1B-A583S;然而,没有额外的基因座包括关注的改变,根据我们的结果。ERG11-Y132F和TAC1B-A583S为耐药基因位点,而CDR1-E709D和TAC1B-Q503E是未鉴定的变异体。
■我们在一个有一些耐药基因的老年女性身上发现了一个特定菌株的C.auris病例,一些基因可能与已经报道的基因位点不同。基因座,突变,和耐药机制研究可能有助于创新药物和治疗方法的创造。临床医生和微生物学家必须意识到这种全球传播的酵母,这构成了医院的实质性诊断,治疗,和感染控制挑战。未来的多中心研究必须进行,以发现这种健康威胁,并提供新的,有效的治疗。
Candida auris (C. auris), a recently developing fungal disease with high
virulence, easy transmission, and substantial medication resistance in hospitals, poses a growing danger to human health. In 2009, the initial documentation of this disease was made when it was discovered in the ear canal of an elderly Japanese patient. Since its initial isolation, the presence of C. auris across six continents has been a cause for severe concern among medical professionals and scientists. According to recent findings, C. auris is connected with five geographically different lineages and significant rates of antifungal resistance. Furthermore, C. auris infections in healthcare settings lack appropriate treatment options and standardized strategies for prevention and control. This results in many treatment failures and hinders the elimination of C. auris in healthcare institutions. To examine the drug resistance mechanism of C. auris and to aid in clinical therapy, we provide a
case of C. auris infection along with a short review of the relevant literature.
An 81-year-old female with cerebral hemorrhage was admitted to the hospital and diagnosed with a urinary catheter-related C. auris. The sample was evaluated and reported in terms of culture, identification, drug sensitivity, and gene sequencing. We also evaluated the relationship between the morphology of the isolated strains and their drug resistance. Whole-genome sequencing yielded the genes ERG11-Y132F, CDR1-E709D, TAC1B-Q503E, and TAC1B-A583S; however, no additional loci included alterations of concern, according to our results. ERG11-Y132F and TAC1B-A583S are drug-resistant gene loci, whereas CDR1-E709D and TAC1B-Q503E are unidentified variants.
We discover a C. auris
case of specific a strain in an old female that has some drug-resistant genes, and some genes may be different from already reported gene sites. Gene locus, mutation, and drug resistance mechanism studies may contribute to the creation of innovative drugs and therapeutic treatments. Clinicians and microbiologists must be aware of this globally spreading yeast, which poses substantial hospital diagnostic, treatment, and infection control challenges. Future multicenter research must be performed to uncover this health threat and provide new, effective treatments.